Oncocyte (NASDAQ:IMDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oncocyte (NASDAQ:IMDX) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other research firms have also recently weighed in on IMDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncocyte in a report on Wednesday, June 24th. Needham & Company LLC restated a “buy” rating and issued a $9.00 target price on shares of Oncocyte in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oncocyte presently has a consensus rating of “Hold” and a consensus target price of $10.50.

Oncocyte Price Performance

NASDAQ:IMDX opened at $4.01 on Friday. The firm has a market capitalization of $131.21 million, a P/E ratio of -2.69 and a beta of 1.80. The business has a 50 day simple moving average of $4.40 and a 200 day simple moving average of $4.71. Oncocyte has a 12-month low of $2.42 and a 12-month high of $8.51.

Oncocyte (NASDAQ:IMDX) last posted its earnings results on Monday, August 10th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.24 million during the quarter.

Oncocyte Company Profile

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy.